Advanced Filters
noise

Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,314 clinical trials
Y Yuqin Song, Doctor

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

18 - 80 years of age All Phase 2
W Weili Zhao, M.D. and Ph.D

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese …

18 years of age All Phase 2

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: have T cells collected from their …

years of age All Phase 1
A Annette Kinsella, RN, CCRC

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets …

18 years of age All Phase N/A

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Researchers also want to …

18 years of age All Phase 1
L Lise Nylund Torpen

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

In this clinical trial adult patients diagnosed with follicular lymphoma and relapse or progression of disease within 24 months of starting first line treatment will be treated with mosunetuzumab. This is a bispecific antibody, a new type of immunotherapy that redirects the bodies own immune cells (T-cells) to attack and …

18 years of age All Phase 2
C Caterina Patti, MD

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.

18 years of age All Phase 2
N Nikita Mochkin, MD, PhD

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

18 - 50 years of age All Phase 3
M Manuel Gotti, Dr

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

The phase I part (safety assessment of the combination treatment) is aimed at determining the MTD of atezolizumab when combined with BEGEV schedule. 6-18 patients enrolled in this part will be treated with atezolizumab in combination with BEGEV regimen every 3 weeks for 4 cycles. Patients without a DLT in …

18 - 60 years of age All Phase 1/2
J John Kuruvilla

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

This is a phase ll study of participants with large B Cell lymphoma previously treated with anti-CD19 Chimeric antigen receptor (CAR-T) therapy. The purpose of the study is to to evaluate the efficacy of zanubrutinib and tislelizumab in patients with progressive lymphoma post anti-CD 19 CAR-T failure.

18 years of age All Phase 2

Simplify language using AI